Long-Term Effects of Ipragliflozin on Diabetic Nephropathy and Blood Pressure in Patients With Type 2 Diabetes: 104-Week Follow-up of an Open-Label Study

BACKGROUND: In our previous study, we investigated the efficacy of ipragliflozin, a sodium-glucose cotransporter (SGLT) 2 inhibitor on diabetic nephropathy in patients with type 2 diabetes and demonstrated that ipragliflozin significantly improved diabetic nephropathy in addition to reducing HbA1c a...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:J Clin Med Res
Egile Nagusiak: Ito, Daisuke, Inoue, Kazuyuki, Sumita, Takashi, Hamaguchi, Keiko, Kaneko, Kimie, Yanagisawa, Morifumi, Inukai, Kouichi, Inoue, Ikuo, Noda, Mitsuhiko, Shimada, Akira
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Elmer Press 2018
Gaiak:
Original Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6089574/
https://ncbi.nlm.nih.gov/pubmed/30116437
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.14740/jocmr3491w
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak